Based on the analysis of two immunotherapy cohorts and the negative correlation between FOXK2 and the expression of nine immune checkpoint genes in most cancer species, our hypothesis is further validated that low expression of FOXK2 indicates better immunotherapy efficacy. The gene discussed is FOXK2; the disease is cancer.